Get the Stockscreener App
3.05
0.66%
0.02
After Hours:
3.10
0.05
+1.64%
Rocket Pharmaceuticals Inc stock is traded at $3.05, with a volume of 1.43M.
It is up +0.66% in the last 24 hours and up +8.54% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.03
Open:
$3.04
24h Volume:
1.43M
Relative Volume:
0.30
Market Cap:
$329.11M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-1.1091
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
+6.64%
1M Performance:
+8.54%
6M Performance:
-70.87%
1Y Performance:
-83.60%
1-Day Range:
$3.035
$3.15
1-Week Range:
$2.83
$3.22
52-Week Range:
$2.19
$22.01
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.05 | 326.95M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Visualizing Rocket Pharmaceuticals Inc. stock with heatmaps2025 Price Action Summary & Long-Term Growth Plans - Newser
Rocket Pharmaceuticals Inc. stock trend outlook and recovery path2025 Top Gainers & Trade Opportunity Analysis - Newser
Risk adjusted return profile for Rocket Pharmaceuticals Inc. Equity Warrant analyzedTrade Ideas & AI Driven Stock Reports - Newser
Custom watchlist performance reports with Rocket Pharmaceuticals Inc.2025 EndofYear Setup & Community Consensus Stock Picks - Newser
Can Rocket Pharmaceuticals Inc. Equity Warrant weather a recessionEntry Point & Low Drawdown Investment Ideas - newsyoung.net
How to build a custom watchlist for Rocket Pharmaceuticals Inc. Equity WarrantTrade Exit Report & Weekly Stock Breakout Alerts - Newser
Volume spikes in Rocket Pharmaceuticals Inc. stock – what they meanJuly 2025 Short Interest & AI Powered Buy/Sell Recommendations - Newser
Using economic indicators to assess Rocket Pharmaceuticals Inc. Equity Warrant potentialWeekly Trend Summary & Community Driven Trade Alerts - Newser
Can a trend reversal in Rocket Pharmaceuticals Inc. lead to recoveryJuly 2025 Volume & Daily Growth Stock Tips - Newser
Has Rocket Pharmaceuticals Inc. Equity Warrant found a price floor2025 Price Momentum & Low Drawdown Investment Ideas - Newser
Rocket Pharmaceuticals Inc. Equity Warrant’s volatility index tracking explainedBreakout Watch & Real-Time Buy Signal Alerts - Newser
Forecasting Rocket Pharmaceuticals Inc. price range with options dataQuarterly Growth Report & Daily Entry Point Alerts - Newser
Rocket Pharmaceuticals: Reprioritization Key To Milestone Achievement By 2026 - Seeking Alpha
Published on: 2025-08-14 16:12:45 - newsyoung.net
Trendlines Converge — Decision Point for Rocket Pharmaceuticals Inc. Equity WarrantMarket Sentiment Review & Risk Controlled Daily Plans - 선데이타임즈
XTX Topco Ltd Cuts Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Chardan Capital Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price - Defense World
Rocket Pharmaceuticals Maintains Hold Rating Amid Clinical and Financial Uncertainties - AInvest
Rocket Pharmaceuticals Faces Investor Lawsuit Over Fatal Gene Therapy Trial – How to Join the Case - TradingView
Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025 - Barchart.com
Deadline coming up on Aug. 11th in Lawsuit for Investors who lost - openPR.com
DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - Business Wire
Rocket Pharmaceuticals Class Action Filed, Deadline August 11, 2025. - AInvest
DEADLINE ALERT for RCKT, TEM, and DDD: The Law Offices of - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesRCKT - PR Newswire
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT)August 11, 2025 Deadline to JoinContact The Gross Law Firm - Barchart.com
Faruqi & Faruqi Reminds Rocket Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025RCKT - PR Newswire
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - MarketScreener
Rocket Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before August 11, 2025 to Discuss Your RightsRCKT - PR Newswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Rocket Pharmaceuticals sued for securities fraud, lead plaintiff deadline Aug. 11. - AInvest
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals - Bluefield Daily Telegraph
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
Is Rocket Pharmaceuticals Inc. Equity Warrant forming a reversal patternReversal Signal Prediction Based on Volume - Newser
What high frequency data says about Rocket Pharmaceuticals Inc.Weekly Gain Forecast with Momentum Indicators - Newser
Will breakout in Rocket Pharmaceuticals Inc. lead to full recoveryProfit Target Planning with Exit Confidence - Newser
RCKT DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class ActionRCKT - ACCESS Newswire
Rocket Pharmaceuticals Hit with Class Action Lawsuit Over Securities Fraud - AInvest
Rocket Pharmaceuticals and the Rocketing Risks in Biotech Innovation - AInvest
Faruqi & Faruqi Investigates Rocket Pharmaceuticals Securities Litigation - AInvest
Combining machine learning predictions for Rocket Pharmaceuticals Inc. Equity Warrant2-Day Signal Watch with Forecast Outcome - Newser
RCKT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 11 Deadline in Securities Class ActionRCKT - ACCESS Newswire
Should you wait for a breakout in Rocket Pharmaceuticals Inc.Profitable Trading Blueprint with Entry Zones - Newser
Rocket Pharmaceuticals Inc. Equity Warrant stock momentum explainedBreakout Watcher with Entry and Exit Alerts - Newser
Class Action Lawsuit Filed: Rocket Pharmaceuticals, Inc. (RCKT)Join by August 11, 2025Contact Levi & Korsinsky - Stockhouse
Class Action Filed Against Rocket Pharmaceuticals, Inc. - GlobeNewswire
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors – Contact Levi & Korsinsky - Morningstar
Rocket Pharmaceuticals and the Biotech Litigation Landscape: Navigating Risks in a High-Stakes Sector - AInvest
Rocket Pharmaceuticals Lawsuit Deadline Approaches: Investors Advised to Contact Law Offices of Frank R. Cruz - AInvest
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):